Welcome to our dedicated page for Lifestance Health Group SEC filings (Ticker: LFST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for LifeStance Health Group, Inc. (Nasdaq: LFST), a mental healthcare company focused on outpatient services. As a public company with common stock registered on The Nasdaq Stock Market LLC, LifeStance files documents such as annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K.
LifeStance’s filings offer detailed information about its business as one of the nation’s largest providers of virtual and in-person outpatient mental healthcare. In these documents, the company describes its operations, risk factors, financial condition and results of operations. For example, current reports on Form 8-K have been used to furnish earnings press releases for specific quarters and to disclose changes in the board of directors, including director resignations and appointments with related equity awards under the company’s equity incentive plan.
Investors can review LifeStance’s discussion of non-GAAP financial measures such as Center Margin and Adjusted EBITDA, along with reconciliations to comparable GAAP measures, within its filings and related exhibits. The company also outlines forward-looking statements and associated risks, referring readers to the "Risk Factors" section of its Form 10-K and subsequent filings for more comprehensive risk disclosures.
On Stock Titan, LifeStance filings are updated as new documents are made available through the SEC’s EDGAR system. AI-powered summaries help explain the key points in lengthy filings, highlight significant changes from prior periods and clarify technical language. Users can quickly identify items related to quarterly and annual results, governance events reported on Form 8-K and other regulatory disclosures relevant to LFST, while still having access to the full original documents for detailed review.
LifeStance Health Group’s Executive Vice President of Practice Operations filed an amended Form 3 updating her insider holdings. She now reports beneficial ownership of 282,495 shares of common stock, including 254,122 unvested restricted stock units, each convertible into one share. The amendment corrects an earlier filing that had inadvertently overstated her holdings by 17,039 shares, which were also mistakenly reflected on subsequent Forms 4.
LifeStance Health Group, Inc. director filed a Form 4 reporting several sales of common stock through affiliated entities in December 2025. On 12/12/2025, Vitthal LLC and Shama LLC each sold 39,815 shares of LifeStance common stock at a weighted average price of $7.01 per share, with individual trades ranging from $7.00 to $7.045.
On 12/15/2025, Vitthal LLC sold 6,186 shares and Shama LLC sold 6,185 shares at a weighted average price of $7.00, with trades between $7.00 and $7.01. Following these transactions, the reporting person is shown as beneficially owning 1,382,175 shares indirectly through Vitthal LLC, 1,498,975 shares indirectly through Shama LLC, 57,619 shares directly, and 36,363 shares indirectly through Alpine Glow Capital, while disclaiming beneficial ownership beyond their pecuniary interests.
LifeStance Health Group, Inc. (LFST)57,240 shares of LifeStance common stock at a weighted average price of $6.43 per share, in multiple trades between $6.41 and $6.50. After these sales, the executive beneficially owns 261,292 shares of LifeStance common stock. The filing notes that full trade details for each price within the range are available upon request.
LifeStance Health Group (LFST)10,623 shares of common stock withheld at $6.43 per share to cover taxes from the net settlement of vested RSUs. The filing notes this was not an open‑market sale.
Following the transaction, the reporting person beneficially owned 318,532 shares directly. The individual is identified as Executive Vice President, Practice Operations.
LifeStance Health Group (LFST) reported a Form 4/A by its Chief People Officer correcting a prior filing. The amendment updates the number of shares withheld for taxes on PSUs vested on March 7, 2025 from 3,725 to 7,450, and updates holdings to 376,430 shares following the reported transactions.
Activity included: a grant of 76,142 RSUs on March 6, 2025; tax withholdings of 6,455 shares at $7.88 on March 6, 2025; PSU vestings of 27,740 and 32,052 on March 7, 2025; and additional tax withholdings of 7,450 shares at $7.59 and 8,606 shares at $7.59. The filing notes these withholdings reduce shares delivered and are not open‑market sales.
LifeStance Health Group (LFST) reported higher Q3 2025 results. Total revenue reached $363.8 million, up from $312.7 million a year ago. Income from operations was $7.4 million versus $0.05 million, and net income was $1.1 million compared with a prior-year net loss. For the first nine months, revenue was $1.04 billion and net loss narrowed to $2.0 million.
Cash and cash equivalents were $203.9 million, and net cash provided by operating activities rose to $88.6 million for the nine-month period. Long-term debt, net, was $269.4 million. Q3 Center Margin was $116.6 million and Adjusted EBITDA was $40.2 million. The company remained in compliance with debt covenants.
Commercial payors represented 90% of Q3 revenue, with government at 5% and self-pay at 4%. The interest rate swap matured on September 30, 2025. As of October 29, 2025, 389,000,281 common shares were outstanding.
LifeStance Health Group, Inc. (LFST) furnished quarterly materials. The company announced it furnished a press release covering results for the third quarter ended September 30, 2025 under Item 2.02, and a supplemental investor slide presentation under Item 7.01.
Both items are furnished, not filed, and are not incorporated by reference into other SEC filings unless expressly referenced. Exhibits include 99.1 (press release dated November 6, 2025) and 99.2 (supplemental slides), along with the Inline XBRL cover page file.
LifeStance Health Group (LFST) reported an insider equity award. A director acquired 74,766 shares of common stock on 08/20/2025 at $0.00, as shown on a Form 4.
The filing states these are restricted stock units (RSUs), with each RSU representing a right to receive one share of common stock. Following the reported transaction, the director beneficially owned 74,766 shares, held directly.
LifeStance Health Group (LFST) filed a Form 3 reporting the initial beneficial ownership of a director as of 08/20/2025. The filing states that no securities are beneficially owned. It was submitted by one reporting person and includes an Exhibit 24 Power of Attorney. This is an administrative disclosure required under Section 16 and does not reflect a transaction.
LifeStance Health Group insider report: Ann Varanakis, Chief People Officer and director, had restricted stock units vest on 08/26/2025. The issuer withheld 5,233 shares to satisfy tax withholding at $5.39 per share; this withholding is a net settlement and not an open-market sale. After the transaction, Ms. Varanakis beneficially owns 369,335 shares. The Form 4 was signed by an attorney-in-fact on 08/27/2025 and indicates the filing was made by one reporting person.
FAQ
What is the current stock price of Lifestance Health Group (LFST)?
What is the market cap of Lifestance Health Group (LFST)?
